Deal Announcements: JATT II Sets Dec. 2 Vote on Talawar Merger
JATT II filed its definitive proxy for a Dec. 2 vote on a Talawar merger backed by a $225 million PIPE and a planned Nasdaq Capital Market listing as TLWR.

JATT II Acquisition Corp., a Cayman Islands SPAC trading on Nasdaq as JATT, filed its definitive proxy statement/prospectus on Nov. 9 and set a Dec. 2 extraordinary general meeting to vote on a merger with Talawar Tx Inc. These deal announcements put a date on a business combination agreement signed on June 29, 2026.
Key takeaways
- The meeting is at 10:00 a.m. Eastern on Dec. 2 at Greenberg Traurig’s offices at One Vanderbilt Avenue in New York, with a virtual option. The record date was Oct. 30.
- Redemption requests are due by 5:00 p.m. Eastern on Nov. 30.
- A $225 million PIPE, priced at $10.00 per share, accompanies the deal, and closing requires at least $125.0 million of available cash.
- The combined company plans to apply to list on the Nasdaq Capital Market as TLWR.
The structure
A Talawar subsidiary, Talawar Merger Sub, will merge into JATT, which survives as a wholly owned subsidiary of Talawar. Talawar, a Delaware corporation, becomes the continuing public company. Each JATT ordinary share converts into one share of the post-closing company’s common stock.
Talawar holders receive a total of $120 million of value, expressed as 12,000,000 shares at $10.00. Just before the merger, Talawar’s convertible instruments and Series L preferred convert to common stock, and Talawar splits its shares by an exchange ratio the proxy assumes at 1.0556. Options are assumed and converted at the same ratio.
| Term | Detail |
|---|---|
| Stock consideration to Talawar holders | 12,000,000 shares ($120 million at $10.00) |
| PIPE | 22,500,000 shares at $10.00, $225 million |
| Minimum available cash | $125.0 million |
| Trust value per public share | About $10.19 (Nov. 3, 2026) |
| Ticker | JATT now; TLWR proposed, subject to Nasdaq approval |
Funding and the business
The companies describe about $285 million of available cash at closing, before transaction costs and assuming no redemptions. That is $60 million in the trust plus the $225 million PIPE, which is led by Access Biotechnology, a founding investor, with participation from Bain Capital Life Sciences, Deep Track Capital, RA Capital Management, Janus Henderson Investors, Farallon Capital Management and others.
Talawar was formed to develop assets discovered by Khanda Therapeutics, L.P. Its lead program, TALA-125, is a bispecific antibody aimed at IL-13 and IL-18 for atopic dermatitis, expected to enter clinical testing in the first quarter of 2027, with interim Phase 1 data in the fourth quarter of 2027. The cash is projected to fund the program through a Phase 2b proof-of-concept readout in the second half of 2028. Two discovery-stage programs, TALA-307 and TALA-711, target other immunology indications.
A related-party angle
JATT’s chairman and chief executive, Dr. Someit Sidhu, recused himself from board deliberations and decisions on the transaction. He is also the founder and CEO of Khanda Therapeutics, which licensed assets to Talawar, and a significant Talawar stockholder, and he controls the sponsor’s general partner. The board approved the agreement unanimously apart from him. The sponsor, JATT Ventures II L.P., holds 1,350,000 founder shares and 300,000 private placement shares and will surrender 150,000 shares at closing.
What shareholders vote on
Holders will consider the business combination as an ordinary resolution and the merger as a special resolution requiring at least two-thirds approval, plus advisory proposals on the charter and organizational documents, and an adjournment proposal if needed. The proxy also registers up to 7,650,000 shares of common stock.
What to watch
The Nov. 30 redemption deadline will show how many public holders take cash near $10.19 a share rather than staying in. The $125.0 million minimum cash condition and Nasdaq’s approval of the TLWR listing are the other gates before the Dec. 2 vote can become a closing.
Prepared with AI assistance from public sources and reviewed under our editorial policy. Not investment advice.

